TY - JOUR
T1 - Monocationic radiotracer kinetics and myocardial infarct size
T2 - A perfused rat heart study
AU - Okada, David R.
AU - Liu, Zhonglin
AU - Beju, Delia
AU - Okada, Robert D.
AU - Johnson, Gerald
N1 - Funding Information:
Acknowledgments The authors are grateful to the American Heart Association for providing grant funding for this study. This study was supported in part by grants from the William K. Warren Medical Research Institute, and the Anne and Henry Zarrow Foundation. The authors gratefully acknowledge the assistance of Mary Marmion with DuPont Pharma in providing kits for the preparation of sestamibi (Cardiolite), Barbara Edwards and George Brauers with Nycomed-Amersham in providing kits for the preparation of tetrofosmin (Myoview) and Karen Deutsch with Monsanto Chemical Company in providing kits for the preparation of Q12. This study is dedicated to the Anne and Henry Zarrow family for their continuing support of medical research, without which these experiments would not have been possible.
Copyright:
Copyright 2009 Elsevier B.V., All rights reserved.
PY - 2008/8
Y1 - 2008/8
N2 - Objective: To compare the myocardial kinetics of three 99mtechnetium-labeled monocationic tracers [methoxy- isobutylisonitrile (MIBI), tetrofosmin, and Q12] in a model of ischemia-reperfusion (IR) to determine their abilities to assess myocardial viability. Methods: Isolated perfused rat hearts (n = 30) were studied in control and IR groups for each tracer. IR hearts were treated with 120 min global no-flow followed by 5 min reflow, then 60 min tracer uptake/clearance. Tracer kinetics were monitored using a scintillation detector. Results: This model produced significant myocardial injury, without significant differences in the percentage of injured myocardium by triphenyltetrazolium chloride (TTC) staining and creatine kinase (CK) assay. Transmission electron microscopy analysis also confirmed necrosis with abundant mitochondrial damage in the IR hearts. All three IR groups exhibited significantly less mean (±standard error of the mean) tracer retention than matched controls (MIBI 73.4 ± 4.9% vs. 96.9 ± 1.76%, tetrofosmin 38.7 ± 4.6% vs. 82.2 ± 3.5%, and Q12 23.0 ± 2.5% vs. 43.8 ± 1.8%, respectively; P < 0.05). Tetrofosmin IR hearts exhibited 54 ± 9% of control myocardial retention, which was significantly less than either MIBI (86 ± 5%, P < 0.05) or Q12 (63 ± 6%, P < 0.05); thus, tetrofosmin provided the best differentiation between nonviable and normal myocardium. Furthermore, tetrofosmin end activity (%id/g) in controls was significantly higher than Q12 (4.09 ± 0.04 vs. 1.71 ± 0.06, respectively, P < 0.05), and tetrofosmin end activity (%id/g) in IR hearts was significantly higher than Q12 (2.19 ± 0.37 vs. 1.06 ± 0.12, respectively, P < 0.05). The correlation between end activity and viable myocardium determined by TTC staining was r = 0.66 (P < 0.05) for MIBI, r = 0.94 (P < 0.05) for tetrofosmin, and r = 0.91 (P < 0.05) for Q12. The correlation between myocardial end activity and myocardial CK leak was r = -0.62 (P < 0.05) for MIBI, r = -0.87 (P < 0.05) for tetrofosmin, and r = -0.89 (P < 0.05) for Q12. Conclusions: Nonviable myocardium can be distinguished from normal myocardium by the retention kinetics of all three monocationic tracers studied. Tetrofosmin and Q12 end activities demonstrate the best correlation with infarct size. However, tetrofosmin kinetics may combine the greatest differentiation between nonviable and normal myocardium, while still retaining adequate activity for imaging.
AB - Objective: To compare the myocardial kinetics of three 99mtechnetium-labeled monocationic tracers [methoxy- isobutylisonitrile (MIBI), tetrofosmin, and Q12] in a model of ischemia-reperfusion (IR) to determine their abilities to assess myocardial viability. Methods: Isolated perfused rat hearts (n = 30) were studied in control and IR groups for each tracer. IR hearts were treated with 120 min global no-flow followed by 5 min reflow, then 60 min tracer uptake/clearance. Tracer kinetics were monitored using a scintillation detector. Results: This model produced significant myocardial injury, without significant differences in the percentage of injured myocardium by triphenyltetrazolium chloride (TTC) staining and creatine kinase (CK) assay. Transmission electron microscopy analysis also confirmed necrosis with abundant mitochondrial damage in the IR hearts. All three IR groups exhibited significantly less mean (±standard error of the mean) tracer retention than matched controls (MIBI 73.4 ± 4.9% vs. 96.9 ± 1.76%, tetrofosmin 38.7 ± 4.6% vs. 82.2 ± 3.5%, and Q12 23.0 ± 2.5% vs. 43.8 ± 1.8%, respectively; P < 0.05). Tetrofosmin IR hearts exhibited 54 ± 9% of control myocardial retention, which was significantly less than either MIBI (86 ± 5%, P < 0.05) or Q12 (63 ± 6%, P < 0.05); thus, tetrofosmin provided the best differentiation between nonviable and normal myocardium. Furthermore, tetrofosmin end activity (%id/g) in controls was significantly higher than Q12 (4.09 ± 0.04 vs. 1.71 ± 0.06, respectively, P < 0.05), and tetrofosmin end activity (%id/g) in IR hearts was significantly higher than Q12 (2.19 ± 0.37 vs. 1.06 ± 0.12, respectively, P < 0.05). The correlation between end activity and viable myocardium determined by TTC staining was r = 0.66 (P < 0.05) for MIBI, r = 0.94 (P < 0.05) for tetrofosmin, and r = 0.91 (P < 0.05) for Q12. The correlation between myocardial end activity and myocardial CK leak was r = -0.62 (P < 0.05) for MIBI, r = -0.87 (P < 0.05) for tetrofosmin, and r = -0.89 (P < 0.05) for Q12. Conclusions: Nonviable myocardium can be distinguished from normal myocardium by the retention kinetics of all three monocationic tracers studied. Tetrofosmin and Q12 end activities demonstrate the best correlation with infarct size. However, tetrofosmin kinetics may combine the greatest differentiation between nonviable and normal myocardium, while still retaining adequate activity for imaging.
KW - Technetium
KW - Ischemia
KW - Myocardial viability
KW - Perfusion imaging agents
KW - Reperfusion
UR - http://www.scopus.com/inward/record.url?scp=50949126781&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=50949126781&partnerID=8YFLogxK
U2 - 10.1007/s12149-008-0155-y
DO - 10.1007/s12149-008-0155-y
M3 - Article
C2 - 18756365
AN - SCOPUS:50949126781
SN - 0914-7187
VL - 22
SP - 617
EP - 627
JO - Annals of Nuclear Medicine
JF - Annals of Nuclear Medicine
IS - 7
ER -